Spots Global Cancer Trial Database for endometrial undifferentiated carcinoma

Every month we try and update this database with for endometrial undifferentiated carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer	NCT02728258	Endometrial End... Endometrial Mix... Endometrial Ser... Endometrial Und... Metastatic Endo... Recurrent Uteri...	Copanlisib Laboratory Biom...	18 Years -	NRG Oncology
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma	NCT05112601	Endometrial Ade... Endometrial Cle... Endometrial Ded... Endometrial End... Endometrial Mix... Endometrial Muc... Endometrial Und... Endometrioid Ad... Recurrent Endom...	Biospecimen Col... Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer	NCT01440998	Endometrial Ade... Endometrial Cle... Endometrial Muc... Endometrial Ser... Endometrial Squ... Endometrial Tra... Endometrial Und... Endometrioid Ad... Recurrent Uteri... Stage III Uteri... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IV Uterin... Stage IVA Uteri... Stage IVB Uteri...	Carboplatin Dasatinib Laboratory Biom... Paclitaxel	18 Years -	National Cancer Institute (NCI)
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer	NCT01225887	Endometrial Ade... Endometrial Cle... Endometrial Muc... Endometrial Ser... Endometrial Squ... Endometrial Tra... Endometrial Und... Malignant Uteri... Recurrent Uteri...	Nintedanib	18 Years -	GOG Foundation
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer	NCT01642082	Endometrial Ade... Endometrial Cle... Endometrial Mix... Endometrial Muc... Endometrial Ser... Endometrial Squ... Endometrial Tra... Endometrial Und... Recurrent Uteri...	Dalantercept Laboratory Biom...	18 Years -	GOG Foundation
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma	NCT05112601	Endometrial Ade... Endometrial Cle... Endometrial Ded... Endometrial End... Endometrial Mix... Endometrial Muc... Endometrial Und... Endometrioid Ad... Recurrent Endom...	Biospecimen Col... Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer	NCT00888173	Endometrial Ade... Endometrial Cle... Endometrial Mix... Endometrial Muc... Endometrial Ser... Endometrial Squ... Endometrial Tra... Endometrial Und... Recurrent Uteri...	Brivanib Alanin... Laboratory Biom...	18 Years -	GOG Foundation
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer	NCT03914612	Endometrial Cle... Endometrial Ded... Endometrial End... Endometrial Mix... Endometrial Ser... Endometrial Und... Recurrent Endom... Recurrent Endom... Recurrent Endom... Recurrent Endom... Recurrent Endom... Recurrent Endom... Recurrent Endom... Recurrent Endom... Stage III Uteri... Stage IV Uterin...	Carboplatin Computed Tomogr... Paclitaxel Pembrolizumab Placebo Adminis... Quality-of-Life... Questionnaire A...	18 Years -	National Cancer Institute (NCI)
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer	NCT01935973	Endometrial Ade... Endometrial Cle... Endometrial Mix... Endometrial Ser... Endometrial Und... Recurrent Uteri...	Laboratory Biom... Trametinib Uprosertib	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone	NCT03660826	Endometrial Ade... Endometrial Mix... Endometrial Ser... Endometrial Und... Endometrioid Ad... Stage IV Uterin...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Capivasertib Cediranib Cediranib Malea... Computed Tomogr... Durvalumab Echocardiograph... Multigated Acqu... Olaparib	18 Years -	National Cancer Institute (NCI)
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer	NCT02728258	Endometrial End... Endometrial Mix... Endometrial Ser... Endometrial Und... Metastatic Endo... Recurrent Uteri...	Copanlisib Laboratory Biom...	18 Years -	NRG Oncology
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer	NCT00575952	Endometrial Ade... Endometrial Cle... Endometrial Mix... Endometrial Ser... Endometrial Squ... Endometrial Und... Recurrent Uteri... Stage IIIA Uter... Stage IIIC Uter... Stage IVA Uteri... Stage IVB Uteri...	Cisplatin Doxorubicin Hyd... Filgrastim Paclitaxel Pegfilgrastim	-	GOG Foundation
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma	NCT05112601	Endometrial Ade... Endometrial Cle... Endometrial Ded... Endometrial End... Endometrial Mix... Endometrial Muc... Endometrial Und... Endometrioid Ad... Recurrent Endom...	Biospecimen Col... Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone	NCT03660826	Endometrial Ade... Endometrial Mix... Endometrial Ser... Endometrial Und... Endometrioid Ad... Stage IV Uterin...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Capivasertib Cediranib Cediranib Malea... Computed Tomogr... Durvalumab Echocardiograph... Multigated Acqu... Olaparib	18 Years -	National Cancer Institute (NCI)
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers	NCT02020707	Cervical Adenoc... Cervical Adenos... Cervical Adenos... Cervical Carcin... Cervical Squamo... Clinical Stage ... Endometrial Ade... Endometrial Cle... Endometrial End... Endometrial Mix... Endometrial Muc... Endometrial Ser... Endometrial Und... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Femal... Malignant Ovari... Malignant Ovari... Malignant Ovari... Malignant Ovari... Malignant Perit... Malignant Solid... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian High Gr... Ovarian Mucinou... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Platinum-Resist... Platinum-Resist... Platinum-Resist... Platinum-Sensit... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Unresectable Me... Uterine Corpus ...	Bevacizumab Laboratory Biom... Nab-paclitaxel Pharmacological...	18 Years -	Mayo Clinic

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: